RED. Sold right off into a micro blip of any strength this AM.
Guess those ole "talks" and "conferences" maybe just don't cut it in the big boy's market of the NASDAQ?
The hedge fund short boys are gonna likely pile on this in droves soon IMO, as OCAT's cash dwindles ever lower and lower and their key trial goes nowhere. $12 million left- for a company that's burning $28 million a yr given the 10-Q rate they just filed (while not running or funding DIME ONE yet of their key Phase II trial)?
It's SHOW ME THE MONEY time IMO- that's what the market place is saying. NO MONEY, no trial(s). It's just that simple. Talk till the cows come home- if there's no cash, it's all for not.
I think it's gonna take a tad more than "talks" and "conferences" to move the needle on this one. Talk is cheap- so they say. Starting and running Phase II, large, FDA quality trials is mega EXPENSIVE. Funny how that reality "works", no?
